Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 151 for your search:
Cancer Type:
Brain tumor, adult: Glioblastoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RTOG-0525
, EORTC-26052, EORTC-22053, NCT00304031
2.
Phase III: Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma.
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
D8480C00055
, NCT00777153
3.
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RTOG-0825
, RTOG 0825, NCT00884741
4.
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
3 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
SJCRH-SJHG04
, GENENTECH-OSI3160s, NCT00124657
5.
A Phase I/II Study of the Photon Radiosurgery System
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 to 32
Sponsor:
Other
Protocol IDs:
CNS 0201
, NCT00179907
6.
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCSF-05103
, 05103, UCSF-H41995-27311-01, NCT00293423
7.
ZD6474 in Treating Patients With Recurrent or Progressive Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0063
, NCI-P6680, NCT00293566
8.
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RTOG-0513
, NCT00305864
9.
Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N0572
, N0572, NCT00329719
10.
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
501007705
, NCT00301418
11.
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-05-02
, NABTC-05-02, NCT00335764
12.
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-0504
, NABTT-0504, NABTT-0504, NCT00379080
13.
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NABTT-0503
, NCT00404248
14.
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
021-003
, NCT00394628
15.
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06-377
, IRUSZACT0018, NCT00441142
16.
Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 120
Sponsor:
Other
Protocol IDs:
R01 CA 89395-01
, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
17.
Radiosurgery for Glioblastoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 65
Sponsor:
Other
Protocol IDs:
2006P-000464
, NCT00456612
18.
Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-0603
, NABTT-0603, 0603, NCT00486603
19.
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UCLA-0604104
, OSI3781s, NCT00509431
20.
VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
NU07C1
, NU 07C1, NCT00516282
21.
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
REO 007
, NCT00528684
22.
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N057K
, N057K, NCT00553150
23.
Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2006-0709
, NCT00555399
24.
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Recovering From Lymphopenia Caused by Temozolomide
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
DUMC-PRO00000580
, PRO00000580, DUMC-SPORE Project 3, NCT00627224
25.
Chemotherapy, Radiation Therapy, and Vaccine Therapy With or Without Daclizumab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
DUMC-PRO00000947
, PRO00000947, DUMC-SPORE II 2003 CMV Grant, NCT00626015
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
